Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
Medtronic
Boehringer Ingelheim
Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Palifermin - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for palifermin
Tradenames:1
Patents:45
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for palifermin
Recent Clinical Trials for palifermin

Identify potential brand extensions & biosimilar entrants

SponsorPhase
City of Hope Medical CenterPhase 1
Spectrum Pharmaceuticals, IncPhase 1/Phase 2
AstraZenecaPhase 1/Phase 2

See all palifermin clinical trials

Pharmacology for palifermin

Company Disclosures: US Patents for palifermin

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Chiron Corporation (Emeryville, CA) 2039-03-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-09-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-10-20 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial The United States as represented by the Department of Health and Human (N/A) (Washington, DC) 2019-07-16 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for palifermin

These patents were identified by searching patent claims

Supplementary Protection Certificates for palifermin

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
06C/006 Belgium   Start Trial PRODUCT NAME: PALIFERMIN; AUTHORISATION NUMBER AND DATE: EU/1/05/314/001 20051027
C005/2006 Ireland   Start Trial SPC005/2006: 20061023, EXPIRES: 20190427
15/2006 Austria   Start Trial PRODUCT NAME: PALIFERMIN
C0016 France   Start Trial PRODUCT NAME: PALIFERMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/05/314/001 DU 20051025; REGISTRATION NO/DATE AT EEC: EU/1/05/314/001 DU 20051025
0217 Netherlands   Start Trial PRODUCT NAME: PALIFERMIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/05/314/001 20051025
0706563/01 Switzerland   Start Trial PRODUCT NAME: PALIFERMIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57334 11.09.2006
0230 Netherlands   Start Trial 300230, 20100130, EXPIRES: 20150129
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
McKesson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.